Skip to content
mapperlab
← Dashboard
Stock

AVXL

ANAVEX LIFE SCIENCES CORP.
Latest close $2.885 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
5
27 funds tracked
Ever held
7
Current + past
New this quarter
1
Exited this quarter
1

Marquee-fund ownership over time

Aug 9, 2024Feb 14, 2025Aug 14, 2025May 15, 2026
Now
5

This quarter's activity

New positions opened

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies re-entered$6.30$2.88-54%
Citadel Advisors$6.18$2.88-53%
Two Sigma Investments$6.18$2.88-53%
D.E. Shaw re-entered$6.18$2.88-53%
AQR Capital Management$6.18$2.88-53%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Point72 Asset Management→ $2.91-28%
Millennium Management→ $10+64%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at ANAVEX LIFE SCIENCES CORP.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
2
Filings · last 90d
2
Total on file
168
Recent SEC buffer
Most recent
Jan 9, 2026

30d / 90d windows measured from Jan 9, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 168 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · ANAVEX LIFE SCIENCES CORP.

Annual figures sourced directly from ANAVEX LIFE SCIENCES CORP.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Net income
-$46.38M
FY2025-8% YoY
EPS (diluted)
$-0.5400
FY2025-4% YoY
Free cash flow(?)
-$39.04M
FY2025-27% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for ANAVEX LIFE SCIENCES CORP. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
D.E. ShawQ2 2026open$2.91$2.88-1%
Point72 Asset ManagementQ1 2026Q2 2026$4.04$2.91-28%
Renaissance TechnologiesQ1 2026open$3.92$2.88-27%
D.E. ShawQ1 2025Q2 2025$8.52$8.37-2%
Citadel AdvisorsQ3 2024open$6.18$2.88-53%
Two Sigma InvestmentsQ3 2024open$6.18$2.88-53%
D.E. ShawQ3 2024Q4 2024$6.18$8.03+30%
AQR Capital ManagementQ3 2024open$6.18$2.88-53%
Millennium ManagementQ3 2024Q3 2025$6.18$10+64%
Renaissance TechnologiesQ3 2024Q3 2025$6.30$11+67%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.